HIGHLIGHTS
5773  Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations
5775  Response to Anti-PD-1 in Microsatellite-Stable Colorectal Cancer: A STAT Need
      Maliha Nusrat
      See related article, p. 5887

5778  Protein Glycosylation: “New-yet-Old” Target for Immunotherapy
      Jaydeep Bhat and Dieter Kabelitz
      See related article, p. 5990

Reviews

5781  Radiation-induced Adaptive Response: New Potential for Cancer Treatment
      C. Norman Coleman, Iris Eke, Adeola Y. Makinde, Sunita Chopra, Sandra Demaria, Silvia C. Formenti, Shannon Martello, Michelle Bylicky, James B. Mitchell, and Molykutty J. Aryankalayil

5791  Statins as Anticancer Agents in the Era of Precision Medicine
      Joseph Longo, Jenna E. van Leeuwen, Mohamad Elbaz, Emily Branchard, and Linda Z. Penn

5801  Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas
      Javier Martin-Broto, David S. Moura, and Brian A. Van Tine

PERSPECTIVES

5809  The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts
      Alex Broom, Katherine Kenny, Alexander Page, Nicole Cort, Eric S. Lipp, Aaron C. Tan, David M. Ashley, Kyle M. Walsh, and Mustafa Khasraw

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORT
5814  Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammapathies: Results of SWOG S0120
      Madhav V. Dhodapkar, Rachael Sexton, Antje Hoering, Frits Van Rhee, Bart Barlogie, and Robert Orlowski

CLINICAL TRIALS: TARGETED THERAPY
5820  Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
      Eva Ciruelos, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sonia Pernas, Laia Paré, Santiago Escrivá-de-Romani, Luis Manso, Barbara Adamo, Eduardo Martínez, Javier Cortés, Silvia Vazquez, Antonia Perelló, Isabel Garau, Mireia Melé, Noelia Martínez, Alvaro Montañó, Begoña Bermejo, Serafin Morales, María J. Echarri, Estela Vega, Blanca González-Farré, Débora Martínez, Patricia Galván, Jordi Canes, Paolo Nuciforo, Xavier Gonzalez, and Aleix Prat

5830  Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5952</td>
<td>Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma</td>
<td>Joske Ubels, Pieter Sonneveld, Martin H. van Vliet, and Jeroen de Ridder</td>
</tr>
<tr>
<td>5962</td>
<td>Translational Cancer Mechanisms and Therapy</td>
<td>Yuta Adachi, Kentaro Ito, Yuko Hayashi, Ryo Kimura, Tuan Zea Tan, Rui Yamaguchi, and Hiromichi Ebi</td>
</tr>
<tr>
<td>5990</td>
<td>Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors</td>
<td>Sailing Shi, Shengqing Gu, Tong Han, Wubing Zhang, Lei Huang, Ziyi Li, Deng Pan, Jingxin Fu, Jun Ge, Myles Brown, Peng Zhang, Peng liang, Kai W. Wucherpfennig, and X. Shirley Liu</td>
</tr>
<tr>
<td>6003</td>
<td>PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer</td>
<td>Katherine D. Gray, Jaclyn E. McCliskey, Yogindra Vedvyas, Olivia R. Kalloo, Steve El Eshaky, Yanping Yang, Enda Shevlin, Marjan Zaman, Timothy M. Ullman, Heng Liang, Dessislava Stefanova, Paul J. Christos, Theresa Scognamiglio, Andrew B. Tassler, Rasa Zarnegar, Thomas J. Fahey III, Moonsoo M. Jin, and Irene M. Min</td>
</tr>
<tr>
<td>6028</td>
<td>Potent Activity of an Anti-ICAM1 Antibody–Drug Conjugate against Multiple Myeloma</td>
<td>Daniel W. Sherbenou, Yang Su, Christopher R. Behrens, Blake T. Aftab, Olivia Perez de Acha, Megan Murnane, Shelby C. Bearrows, Byron C. Hann, Jeffery L. Wolf, Thomas G. Martin, and Bing Liu</td>
</tr>
<tr>
<td>6039</td>
<td>Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma</td>
<td>Charles Marusak, Varsha Thakur, Yuan Li, Juliano T. Freitas, Patrick M. Zmina, Vijay S. Thakur, Mayland Chang, Ming Gao, Jiufeng Tan, Min Xiao, Yiling Lu, Gordon B. Mills, Keith Flaherty, Dennie T. Frederick, Benchun Mia, Ryan J. Sullivan, Tabea Moll, Genevieve M. Boland, Meenhard Herlyn, Gao Zhang, and Barbara Bedogni</td>
</tr>
<tr>
<td>6051</td>
<td>CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma</td>
<td>Andrew Cannon, Christopher M. Thompson, H. Carlo Maurer, Pranita Atri, Rakesh Bhatia, Sean West, Dario Gheri, Kenneth P. Olive, Sushil Kumar, and Surinder K. Batra</td>
</tr>
<tr>
<td>6064</td>
<td>Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer</td>
<td>Cameron M. Armstrong, Chengfei Liu, Liangren Liu, Joy C. Yang, Wei Lou, Ruining Zhao, Shu Ning, Alan P. Lombard, Jinge Zhao, Leandro S. D’Abronzo, Christopher P. Evans, Pui-Kai Li, and Allen C. Gao</td>
</tr>
</tbody>
</table>

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org
Multiplex immunofluorescence for PI3K pathway activation on a single cell-level, using formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue on tissue microarrays (TMA). The merged image shows the following markers: PTEN (orange), stathmin (aqua), phosphoS6 (green), p63 (red), AMACR (yellow), and DAPI counterstain (blue) in a TMA core with both normal tissue (center) and invasive tumor tissue. For details, see the article by Stopsack and colleagues on page 5903 of this issue.